UNSPSC 51283949: Sulfamerazine sodium

This classification denotes a sulfonamide anti-infective agent with the molecular formula C11H11N4O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JOV4UJY07O, chemically known as sulfanilamide, n(sup 1)-(4-methyl-2-pyrimidinyl)- but more generally known as sulfamerazine sodium, which bears US NIH Compound Identifier 5325. European Medicines Agency schedules Sulfamerazine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10709MIG.

UNSPSC 51283949 Sulfamerazine sodium is a Commodity code that nominally addresses a specific pharmaceutical active ingredient, but recent state and local solicitations tagged with this code show minimal direct relevance to sulfamerazine itself. Instead, the opportunities under this code reflect broader pharmaceutical and medical supply procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs. State and local issuing bodies using this code span counties (Seminole County, Florida), cities (City of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work being solicited centers on annual supply contracts for emergency medical products, pharmacy benefit program administration, and medical consumables for fire and rescue operations, with most opportunities structured as RFPs, RFQs, or ITBs and most requiring compliance with federal drug-supply chain security standards, cGMP certification, and FDA registration.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative vehicle extending reach to Oregon and other member jurisdictions. Recent representative opportunities include Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the City of Tampa's ITB 26P00145 for medical and first aid supplies supporting the Tampa Fire Department Rescue Division with an estimated contract value of $700,000.00 and an SLBE sheltered-market designation (due March 13, 2026), the Texas HHS Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription programs (posted April 3, 2026), and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The MMCAP opportunity requires vendors to work through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and mandates cGMP certification and DSCSA compliance, with pricing weighted at 75 percent of the evaluation. The mismatch between the code's nominal scope and actual procurement activity suggests this code may be misapplied to broader pharmaceutical and medical-supply categories in some state and local systems.